Department of Obstetrics and Gynecology, Ulm University, Prittwitzstrasse 43, 89075 Ulm, Germany.
FASEB J. 2012 May;26(5):2094-104. doi: 10.1096/fj.11-200790. Epub 2012 Jan 25.
Most presently known breast cancer susceptibility genes have been linked to DSB repair. To identify novel markers that may serve as indicators for breast cancer risk, we performed DSB repair analyses using a case-control design. Thus, we examined 35 women with defined familial history of breast and/or ovarian cancer (first case group), 175 patients with breast cancer (second case group), and 245 healthy women without previous cancer or family history of breast cancer (control group). We analyzed DSB repair in peripheral blood lymphocytes (PBLs) by a GFP-based test system using 3 pathway-specific substrates. We found increases of microhomology-mediated nonhomologous end joining (mmNHEJ) and nonconservative single-strand annealing (SSA) in women with familial risk vs. controls (P=0.0001-0.0022) and patients with breast cancer vs. controls (P=0.0004-0.0042). Young age (<50) at initial diagnosis of breast cancer, which could be indicative of genetic predisposition, was associated with elevated SSA using two different substrates, amounting to similar odds ratios (ORs=2.54-4.46, P=0.0059-0.0095) as for familial risk (ORs=2.61-4.05, P=0.0007-0.0045). These findings and supporting validation data underscore the great potential of detecting distinct DSB repair activities in PBLs as method to estimate breast cancer susceptibility beyond limitations of genotyping and to predict responsiveness to therapeutics targeting DSB repair-dysfunctional tumors.
目前已知的大多数乳腺癌易感基因都与 DSB 修复有关。为了确定可能作为乳腺癌风险指标的新标记物,我们采用病例对照设计进行了 DSB 修复分析。因此,我们检查了 35 名具有明确家族性乳腺癌和/或卵巢癌病史的女性(第一病例组)、175 名乳腺癌患者(第二病例组)和 245 名无既往癌症或乳腺癌家族史的健康女性(对照组)。我们使用 3 种途径特异性底物的基于 GFP 的测试系统分析了外周血淋巴细胞(PBL)中的 DSB 修复。我们发现,与对照组相比,具有家族风险的女性和乳腺癌患者的微同源介导的非同源末端连接(mmNHEJ)和非保守性单链退火(SSA)增加(P=0.0001-0.0022 和 P=0.0004-0.0042)。乳腺癌首次诊断时年龄较轻(<50 岁)可能提示遗传易感性,与两种不同底物的 SSA 升高相关,其比值比(OR)相似(OR=2.54-4.46,P=0.0059-0.0095),与家族风险(OR=2.61-4.05,P=0.0007-0.0045)相似。这些发现和支持的验证数据强调了在 PBL 中检测不同 DSB 修复活性作为估计乳腺癌易感性的方法的巨大潜力,超越了基因分型的限制,并预测对针对 DSB 修复功能障碍肿瘤的治疗的反应性。